Introduction
============

Asthma and COPD are the leading causes of morbidity and mortality worldwide and are associated with significant economic and social burdens.[@b1-copd-11-953],[@b2-copd-11-953] They are traditionally viewed as distinct clinical entities. Asthma is typically recognized as an allergic disease, often affecting children and young adults, characterized by reversible airflow obstruction and favorable prognosis. In contrast, COPD is typically caused by tobacco smoking, usually affects adults aged \>40 years, and displays persistent airflow obstruction, resulting in progressive decline in lung function and premature death.[@b3-copd-11-953] However, some patients may have clinical features of both asthma and COPD, which is called the asthma--COPD overlap syndrome (ACOS).[@b4-copd-11-953] Compared with asthma or COPD alone, ACOS is associated with more frequent exacerbations and hospitalizations and a higher overall health care burden and mortality.[@b5-copd-11-953]--[@b8-copd-11-953] Therefore, making an accurate diagnosis of ACOS is very important.

Although ACOS has been accepted as a distinct disease by Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD), the diagnostic criteria remain unclear.[@b4-copd-11-953] To date, there is little established evidence regarding its diagnosis and treatment, as ACOS patients have been excluded from clinical trials for both asthma and COPD.[@b4-copd-11-953] Therefore, differentiating ACOS from asthma and COPD is challenging.

Emphysema is an important pathological feature of COPD. It is defined as "abnormal permanent enlargement of air spaces distal to terminal bronchioles, accompanied by destruction of their walls without obvious fibrosis".[@b9-copd-11-953] Varying extents of emphysema and small airway disease lead to persistent airflow obstruction in COPD.

Unlike COPD, asthma was considered to be predominantly an airway disease, generally without destruction of lung parenchyma (emphysema).[@b10-copd-11-953] However, previous studies have shown that some asthma patients also had signs of emphysema as shown on computed tomography (CT) of the chest.[@b11-copd-11-953] Gelb et al[@b12-copd-11-953] even found mild emphysema on histopathology of nonsmoking patients with asthma. These asthma patients have signs of emphysema, suggesting the coexistence of COPD. Evaluating the extent of emphysema may identify asthma patients with coexisting COPD, which may facilitate the diagnosis of ACOS.

Quantitative CT is a promising technique, because it has made repeated and noninvasive measurements of structural changes in the lungs possible.[@b13-copd-11-953],[@b14-copd-11-953] Emphysema is characterized by areas of reduced attenuation coefficients in the lungs on CT.[@b15-copd-11-953] The severity of emphysema is generally quantified as the percentage of "low attenuation area" (LAA) in the lungs with Hounsfield units (HU) less than a specific threshold (eg, −950 HU; %LAA-950).[@b16-copd-11-953] Previous studies have demonstrated that the measurements of emphysema in quantitative CT correlate well with the visual scoring systems and pathology measurements.[@b13-copd-11-953],[@b16-copd-11-953]

There is little evidence on the diagnostic value of quantitative CT measurements of emphysema for ACOS. We hypothesized that quantitative CT measurement of emphysema may detect asthma patients with signs of emphysema and those patients may fulfill the characteristics of ACOS. We aimed to: 1) establish the normal range of %LAA-950 in Chinese patients aged \>40 years; 2) compare the quantitative CT measurements and emphysema distribution between normal, asthma, and COPD patients; 3) investigate the value of quantitative CT measurements of emphysema in the diagnosis of ACOS; and 4) investigate the predictors of high emphysema index (EI) in patients with asthma.

Methods
=======

Subjects
--------

This study is part of a prospective observational study being performed at Qilu Hospital, People's Republic of China. We recruited 404 participants: 125 with COPD, 151 with asthma, and 128 normal controls. All the participants were mainland Chinese, aged between 40 and 85 years, who presented to the Qilu Hospital between July 2013 and November 2015.

On the basis of GINA guidelines, asthma was diagnosed as respiratory symptoms such as wheezing and shortness of breath varying over time and in intensity, together with variable expiratory airflow limitation (post-bronchodilator \[BD\] improvement in forced expiratory volume in 1 second \[FEV~1~\] \>12% and \>200 mL or average daily diurnal peak expiratory flow variability \>10% over 2 weeks).[@b17-copd-11-953] Those asthma patients with persistent airflow limitation (the potential ACOS patients) were also enrolled in the asthma group. Patients were diagnosed with COPD based on \>10 pack-years smoking history or confirmed noxious gas or particle exposure, physical examination, respiratory symptoms, and persistent airflow limitation (post-BD FEV~1~/forced vital capacity \[FVC\] \<0.70), according to the GOLD guidelines.[@b18-copd-11-953] Patients with asthma syndrome or history of asthma were excluded from the COPD group. Controls were recruited from healthy nonsmokers aged between 40 and 85 years with normal spirometry (FEV~1~ ≥80% predicted and FEV~1~/FVC ≥0.7) who underwent chest CT for health examination. Those who had a history of lung disease or pulmonary nodules \>1 cm in high-resolution CT (HRCT) were excluded from the normal control group.

We excluded patients with: 1) acute exacerbation within the past 6 weeks; 2) other lung diseases such as extensive bronchiectasis, cystic fibrosis, interstitial lung disease, lung cancer, or infectious lung disease; 3) pulmonary masses \>3 cm on chest CT; 4) severe comorbid conditions, such as congestive heart failure, severe hepatic and renal dysfunction, cancer, malnutrition, or severe anemia; and 5) any cognitive disorder.

All participants completed standardized questionnaires and underwent pulmonary function tests (PFTs) and HRCT on the same day. Demographic characteristics and acute exacerbations of the previous year were recorded.

The study was approved by the Ethics Committee of Qilu Hospital of Shandong University (No 2015091). All participants gave written informed consent to participate in the study.

PFTs
----

After the patients inhaled a short-acting β-agonist for 15 minutes; PFTs were performed on a computerized spirometer (MasterScreen, Jaeger, Hoechberg, Germany) according to the American Thoracic Society and the European Respiratory Society (ATS/ERS) recommendations.[@b19-copd-11-953] Basic information, including age, height, weight, and spirometry data (FEV1.0, FVC, FEV1.0/FVC, FVC, and vital capacity \[VC\]), were collected. Post-BD FEV~1~/FVC \<0.70 was termed as airflow limitation.[@b18-copd-11-953]

HRCT scanning
-------------

Chest HRCT was performed at maximal inspiration with the participants in supine position using a 64-slice spiral CT scanner (SOMATOM Definition AS, Siemens Healthcare, Erlangen, Germany). Tube voltage was 120 kV and tube current varied by automatic regulation, based on slice location and participants' body habitus. The exposure time was 0.5 second and the matrix size was 512×512 pixels. Images were contiguously reconstructed with a 1 mm slice thickness (with 0.625 mm overlapping), using a standard algorithm.

CT measurements of emphysema
----------------------------

All CT images were automatically analyzed by Airway Inspector software (Surgical Planning Laboratory at Brigham and Women's Hospital, Boston, MA, USA). The extent of emphysema was measured by the density mask and percentile point methods. For the density mask method, emphysema was quantified by percentage of lung voxels with CT attenuation value below −950 HU (%LAA-950) or −910 HU (%LAA-910) on the inspiratory images. For the percentile point method, emphysema was measured as mean lung attenuation at the 10th or 15th percentile on lung attenuation curve (LP10A, LP15A).[@b16-copd-11-953],[@b20-copd-11-953] Previous studies have shown that %LAA-950 has the strongest correlation with emphysema at both the macroscopic and microscopic levels among all the emphysema indicators measured by quantitative CT.[@b21-copd-11-953],[@b22-copd-11-953] %LAA-950 is also the most common used parameter in previous studies.[@b14-copd-11-953],[@b16-copd-11-953],[@b20-copd-11-953] For this reason, %LAA-950 was selected as the major indicator of pulmonary emphysema and defined it as "EI".

In order to study the distributions of emphysema, the lungs were divided into three regions with equal volume: upper, middle, and lower. The EI of each region was calculated. The distributions of EI were classified as: 1) upper-lung-zone predominance (ULP): the EI of upper lung zone was higher than that of middle and lower lung zones, and the difference between the upper and lower lung zones was \>10%; 2) lower-lung-zone predominance: the EI of lower lung zone was higher than that of middle and upper lung zones, and the difference between the upper and lower lung zones was \>10%; and 3) middle/homogeneous distribution: the EI of middle lung zone was higher than both the upper and the lower lung zones or the difference between the upper and lower lung zones was \<10%.[@b23-copd-11-953],[@b24-copd-11-953] The relative amount of ULP (per ULP) in groups was also calculated.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 19.0 (IBM Corporation, Armonk, NY, USA). A *P*-value of \<0.05 was deemed statistically significant. Demographic and clinical characteristics of all subjects were summarized descriptively. Quantitative data were expressed as mean ± standard deviation (SD). Quantitative data of asthma, COPD, and control participants were compared using the Kruskal--Wallis test followed by pairwise multiple comparisons with Bonferroni correction. The sex ratio and distributions of emphysema were compared using chi-square test. The Mann--Whitney *U* test was used to assess the differences between quantitative variables. Binary logistic regression models were used to identify predictive factors of the presence of high EI in asthma patients by a stepwise method, with a probability value for entry (*P*=0.05) and removal (*P*=0.10).

Results
=======

Participants' characteristics
-----------------------------

We included 404 participants; 151 asthma, 125 COPD, and 128 control participants. The clinical characteristics of each group are shown in [Table 1](#t1-copd-11-953){ref-type="table"}. Compared with asthma and control participants, those with COPD were older (*P*\<0.001), had greater pack-years of smoking (*P*\<0.001), and had a lower body mass index (BMI) (*P*\<0.05). The pulmonary function parameters, including FEV1.0, FEV1.0/FVC, FVC, and VC, were worse in COPD patients compared with those with asthma (*P*\<0.001). There was no significant difference in acute exacerbations per year between asthma and COPD patients (*P*=0.436).

The normal range of EI and emphysema distribution of controls
-------------------------------------------------------------

The mean %LAA-950, called the EI, in the controls was 2.79%±2.37%. There were no significant differences in EI between males (2.81±1.96) and females (2.75±3.2, *P*=0.091). As shown in [Table 2](#t2-copd-11-953){ref-type="table"}, 65.5% (84/182) of normal controls were middle/homogeneous distribution and only 16.4% (21/128) were upper-zone-predominant distribution. Participants were considered to have high EI if %LAA-950 exceeded 9.9%, corresponding to three SDs above the mean in controls.[@b25-copd-11-953]

Comparison of emphysema measurements between normal controls, COPD, and asthma patients
---------------------------------------------------------------------------------------

Emphysema measurements of control, asthma, and COPD participants are shown in [Table 2](#t2-copd-11-953){ref-type="table"}. COPD patients had significantly higher EI (15.84±11.90) than patients with asthma (6.19±6.79, *P*\<0.001) and controls (2.79±2.37, *P*\<0.001). Other emphysema measurements including %LAA-910, LP10A, and LP15A were also higher in COPD patients than in patients with asthma (*P*\<0.001) and controls (*P*\<0.001). These results were consistent with the presence of emphysema in COPD patients. The emphysema distributions of asthma patients, COPD patients, and controls were significantly different (*P*\<0.001). More COPD patients showed upper-zone-predominant distribution (48.8%) than asthma patients (16.4%, *P*\<0.001) and controls (18.0%, *P*\<0.001). The EI and other emphysema measurements (%LAA-910, LP10A, and LP15A) of asthma patients were higher than controls (*P*\<0.001). This suggests that some asthma patients may have emphysema; therefore, we investigated the clinical characteristics of asthma patients with high EI.

Comparison between asthma patients with high and low EI
-------------------------------------------------------

We used three SDs above the mean %LAA-950 of controls (%LAA-950=9.9%) as a cutoff of high EI. Out of 151 asthma patients, 32 (21.2%) had high EI and 119 (78.8%) had low EI. In the COPD group, 66.4% (83/125) of patients had high EI. [Table 3](#t3-copd-11-953){ref-type="table"} shows the comparison of characteristics between asthma patients with high and low EI. Compared with asthma patients with low EI, those with high EI were significantly older (*P*=0.046), had lower BMI (*P*\<0.001), were more likely to be male (*P*\<0.001), had higher pack-years of smoking (*P*\<0.001), and had a greater number of acute exacerbations per year (*P*\<0.001). More asthma patients with high EI were ULP (34.4%) than those with low EI (13.4%, *P*\<0.001). Regarding PFTs, all asthma patients with high EI had airflow limitation, but only 64.05% of those with low EI had airflow limitation. The FEV~1~% predicted values and FEV~1~/FVC% were significantly lower in asthma patients with high EI than those with low EI. There was no significant difference in VC (*P*=0.133) or FVC (*P*=0.097) between these patients. These results show that the characteristics of asthma patients with high EI (severe and persistent airflow limitation, older age, more tobacco smoke exposure, and more upper-zone-predominant emphysema) were similar to those of COPD patients.

Comparison of patients with COPD and asthma with high EI
--------------------------------------------------------

We compared the clinical characteristics and emphysema measurements of patients with asthma having high EI with those with COPD ([Table 4](#t4-copd-11-953){ref-type="table"}). Compared with COPD patients, asthma patients with high EI were younger (*P*=0.025) and had more acute exacerbations per year (*P*=0.012). There was no significant difference in sex (*P*=0.494) or BMI (*P*=0.918) between the groups. The FVC and VC of asthma patients with high EI were significantly higher than COPD patients, but there were no significant differences in FEV1.0% predicted (*P*\>0.1) and FEV1.0/FVC (*P*\>0.1). Additionally, there was no significant difference in %LAA-950 (*P*=0.152) and per ULP (*P*=0.862) of the two groups. These results showed that asthma patients with high EI had similar clinical features (age, sex, BMI, airflow limitation, tobacco smoke exposure, and emphysema distribution) to COPD patients.

Predictors of high EI in asthma patients
----------------------------------------

Six variables were included in a logistic regression model: age (per decade), sex, BMI, pack-years of smoking (per 10 pack-years), FEV1% predicted (per 10% decrease), and acute exacerbations. Using the stepwise method, age and sex were not found to be associated with the presence of high EI in asthma patients (*P*\>0.05). As shown in [Table 5](#t5-copd-11-953){ref-type="table"}, pack-years of smoking (odds ratio \[OR\] =1.405, *P*=0.003), acute exacerbations (OR=2.72, *P*=0.005), and FEV1% predicted decrease (OR=1.428, *P*=0.013) are positive predictive factors of asthma patients with high EI. The presence of high EI was less likely in asthma patients with high BMI.

Discussion
==========

In the present study, COPD patients had a higher extent of emphysema on quantitative CT than asthma patients or controls. The normal range of %LAA-950 in Chinese aged \>40 years was 2.79%±2.37%. Compared with asthma patients with low EI, those with high EI were significantly older, more likely to be male, had higher pack-years of smoking, had more acute exacerbations, had more upper-zone-predominant emphysema, and had greater airflow limitation. Compared with COPD patients, asthma patients with high EI were younger and had more frequent acute exacerbations. There was no significant difference in sex ratios, pack-years smoking, FEV1.0/FVC, EI, or emphysema distribution between asthma patients with high EI and those with COPD.

Although the concept of ACOS is widely accepted, little is known about its diagnosis and treatment. To date, there is no blood test or other method of assessment that provides simple criteria for the diagnosis of ACOS. Asthma and COPD have different pulmonary function manifestations, airway inflammation types, and lung structure changes. Functional and inflammatory biomarkers, including BD test and eosinophilia in sputum, were recommended as part of the diagnostic criteria of ACOS in the Spanish COPD and GOLD guidelines.[@b4-copd-11-953],[@b26-copd-11-953] However, the measurements of lung structural changes have not been included in the current guidelines. As per our knowledge, this is the first study that has focused on the value of quantitative CT measurements of emphysema in the diagnosis of ACOS.

Emphysema measurements in quantitative CT are highly reproducible and correlate well with visual scoring systems and pathology measurements.[@b13-copd-11-953],[@b27-copd-11-953],[@b28-copd-11-953] In addition, emphysema assessment by quantitative CT is related to a decline in lung function, and mortality in COPD patients.[@b29-copd-11-953],[@b30-copd-11-953] Quantitative CT can also quantify large airway dimensions in chronic airway disease. However, previous studies show that the current quantitative CT technologies may overestimate the airway wall thickness.[@b31-copd-11-953],[@b32-copd-11-953] Additionally, small airways (diameter \<2 mm), which play a critical role in the pathogenesis of asthma and COPD, cannot be depicted by HRCT because their thin walls are below the resolving power of HRCT.[@b32-copd-11-953],[@b33-copd-11-953] Therefore, airway dimensions were not measured in this study.

Until now, only a few studies have focused on the normal range of quantitative CT measurements of emphysema in the Chinese population. In this study, %LAA-950 of controls aged \>40 years was 2.79%±2.37% compared with 2.0%±2.7% in the COPDGene study.[@b34-copd-11-953] The COPDGene study suggested that %LAA-950 was higher in males than females in healthy nonsmoking adults.[@b34-copd-11-953] However, such a difference was not noted in the present study. This may be due to differences in the race of study populations. In addition, the scanner models and different quantitative CT softwares may also influence the emphysema measurements.

Significantly higher quantitative CT emphysema parameters were found in COPD patients compared with patients with asthma and controls. This is consistent with the presence of emphysematous destruction in COPD patients. Besides the difference in the severity of emphysema, the emphysema distribution is also significantly different in COPD and asthma patients. More COPD patients are ULP than asthma patients, which is consistent with the fact that emphysema is more likely to involve the upper lung lobes in COPD.[@b35-copd-11-953] These results suggest that extent and distribution of emphysema measured by quantitative CT may contribute to the differential diagnosis of COPD and asthma.

Using the cutoff point of %LAA-950=9.9%, 21.2% of asthma patients aged \>40 years were noted to have high EI, indicating the presence of emphysema. Compared with asthma patients with low EI, those with high EI had higher pack-years of smoking. Using logistic regression method, pack-years of smoking (per 10 pack-years), acute exacerbations, FEV~1~% predicted (per 10% decrease), and BMI were associated with high EI among asthma patients. Repeated smoke-induced injury and repair could lead to alveolar wall destruction and apoptosis of epithelial and endothelial cells, thereby causing emphysema.[@b36-copd-11-953] These results suggest that some asthma patients may develop emphysematous lung destruction because of the exposure to toxic gases and particles. The underlying mechanisms and potential clinical impact of emphysema in asthma patients need further investigation.

Compared with asthma patients with low EI, those with high EI were older, more likely to be male, and had more severe airflow limitation. These results are consistent with the findings of a previous study demonstrating that asthma patients with emphysema were significantly older and more likely to be male than those without emphysema.[@b37-copd-11-953] The greater airflow limitation may be due to loss of lung tissue elasticity and small airway collapse during exhalation caused by emphysema. There were no significant differences in sex, smoking history, extent of airflow limitation, and EI between asthma patients with high EI and those with COPD. These results suggest that some patients with asthma have high EI on quantitative CT. Asthma patients with high EI have pathological (high extent of emphysema, more upper-predominant-emphysema) and clinical features (old age, smoking history, severe airflow limitation) similar to COPD patients, suggesting ACOS. These asthma patients fulfill the characteristics of ACOS described in the GINA and GOLD guidelines.[@b4-copd-11-953] Therefore, quantitative CT measurements of emphysema may be useful in the diagnosis of ACOS.

There was no significant difference in ΔFEV~1~ in bronchial dilation test between asthma patients with high and low EI, but the percentage of ΔFEV~1~ was significantly higher in those with high EI. One possible explanation for this is that the baseline FEV1.0 is lower in asthma patients with high EI. The ΔFEV~1~ were significantly higher in asthma patients with high EI than COPD patients. A previous study demonstrated that ACOS patients have greater response to BDs than COPD patients.[@b38-copd-11-953] This result suggests that bronchial dilation test may help in distinguishing ACOS from COPD patients.

Previous studies have shown that ACOS patients have a greater number of acute exacerbations than those with COPD or asthma alone.[@b5-copd-11-953],[@b6-copd-11-953] In this study, a greater number of acute exacerbations were found in asthma patients with high EI compared with those with asthma and low EI or COPD. Frequent exacerbations are strongly associated with long-term morbidity and mortality in asthma and COPD.[@b39-copd-11-953] These findings would suggest that management of asthma patients with high EI should be directed toward exacerbation prevention.

Quantitative CT is a promising technique in the diagnosis and evaluation of chronic airway diseases. Although quantitative CT allows repeated, noninvasive evaluation of emphysema, the measurement of emphysema can be influenced by many factors, including image reconstruction algorithm, section thickness, inspiration level, radiation dose, and scanner/study center.[@b16-copd-11-953] There are still no widely accepted standards for the evaluation of emphysema in quantitative CT. More research is needed before the application of quantitative CT in clinical practice.

Limitations
===========

Our study had several limitations. First, this is a cross-sectional study and therefore we were not able to study clinical outcomes of the participants. Second, this study was conducted at a single institute. Third, we had a small sample size. Further prospective studies involving multicenter and large sample size of patients are needed.

Conclusion
==========

Some asthma patients have high EI on quantitative CT with clinical features (age, tobacco smoking, extent of airflow limitation, extent, and distribution of emphysema) similar to those of COPD. These patients had more frequent acute exacerbations than asthma patients with low EI and those with COPD. The clinical features of asthma patients with high EI fulfill the characteristics of ACOS described in the GINA and GOLD guidelines.[@b4-copd-11-953] Quantitative CT measurements of emphysema, therefore, may help diagnose ACOS.
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###### 

Characteristics of participants

  Characteristics               Controls (n=128)   Asthma (n=151)                                             COPD (n=125)                                                                                         *P*-value
  ----------------------------- ------------------ ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Age, years                    59.8±8.5           58.2±9.4[\*\*\*](#tfn4-copd-11-953){ref-type="table-fn"}   65.8±9.3[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}    \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
  Sex, female/male              49/79              81/70                                                      32/93                                                                                                \<0.001[b](#tfn7-copd-11-953){ref-type="table-fn"}
  BMI, kg/m^2^                  24.3±3.3           25.5±3.9[\*\*](#tfn3-copd-11-953){ref-type="table-fn"}     22.6±4.5[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}    \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
  Smoking, pack-years           0                  12.1±21.8[\*](#tfn2-copd-11-953){ref-type="table-fn"}      34.5±26.6[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
  Current/former/never smoker   0/0/128            28/23/100                                                  57/49/19                                                                                             \<0.001[b](#tfn7-copd-11-953){ref-type="table-fn"}
  Acute exacerbations           NA                 1.1±0.8                                                    1.2±0.9                                                                                              0.436[c](#tfn8-copd-11-953){ref-type="table-fn"}
  Postbronchodilator                                                                                                                                                                                               
   FEV~1~ % predicted           100.9±13.2         65.1±22.5[\*](#tfn2-copd-11-953){ref-type="table-fn"}      44.3±18.6[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
   FVC% predicted               103.4±13.9         88.5±18.1[\*](#tfn2-copd-11-953){ref-type="table-fn"}      73.6±17.5[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
   VC% predicted                103.9±13.2         88.9±17.1[\*](#tfn2-copd-11-953){ref-type="table-fn"}      76.0±16.2[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
   FEV~1~/FVC%                  81.3±5.2           60.5±13.9[\*](#tfn2-copd-11-953){ref-type="table-fn"}      48.1±12.2[\*](#tfn2-copd-11-953){ref-type="table-fn"},[\#](#tfn5-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn6-copd-11-953){ref-type="table-fn"}
  Response to β~2~-agonist                                                                                                                                                                                         
   ΔFEV~1~, L                   NA                 0.305±0.033                                                0.143±0.009                                                                                          \<0.001[c](#tfn8-copd-11-953){ref-type="table-fn"}
   % change in FEV~1~ %         NA                 22.4±16.4                                                  15.2±12.8                                                                                            \<0.001[c](#tfn8-copd-11-953){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD.

*P*\<0.01,

*P*\<0.05,

*P*\>0.05 versus controls;

*P*\<0.01 versus asthma patients.

Analysis of Kruskal--Wallis test.

Analysis of chi-square test.

Analysis of Mann--Whitney *U* test.

**Abbreviations:** BMI, body mass index; ΔFEV~1~, increases in forced expiratory volume in 1 second; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity;NA, not applicable; SD, standard deviation; VC, vital capacity.

###### 

Emphysema measurements of asthma, COPD, and control participants

                           Controls (n=128)   Asthma (n=151)                                               COPD (n=125)                                                                                             *P*-value
  ------------------------ ------------------ ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  %LAA-950, %              2.79±2.37          6.19±6.79[\*](#tfn11-copd-11-953){ref-type="table-fn"}       15.84±11.90[\*](#tfn11-copd-11-953){ref-type="table-fn"},[\#](#tfn13-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn14-copd-11-953){ref-type="table-fn"}
  %LAA-910, %              21.07±20.06        26.20±18.78[\*\*](#tfn12-copd-11-953){ref-type="table-fn"}   40.97±17.75[\*](#tfn11-copd-11-953){ref-type="table-fn"},[\#](#tfn13-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn14-copd-11-953){ref-type="table-fn"}
  LP10A, HU                −914.7±23.0        −924.1±32.0[\*](#tfn11-copd-11-953){ref-type="table-fn"}     −954.3±25.9[\*](#tfn11-copd-11-953){ref-type="table-fn"},[\#](#tfn13-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn14-copd-11-953){ref-type="table-fn"}
  LP15A, HU                −905.9±24.7        −914.8±33.5[\*](#tfn11-copd-11-953){ref-type="table-fn"}     −944.0±26.7[\*](#tfn11-copd-11-953){ref-type="table-fn"},[\#](#tfn13-copd-11-953){ref-type="table-fn"}   \<0.001[a](#tfn14-copd-11-953){ref-type="table-fn"}
  Per high EI, %           0                  32 (21.2%)                                                   83 (66.4%)                                                                                               \<0.001[b](#tfn15-copd-11-953){ref-type="table-fn"}
  Upper zone EI, %         2.51±2.35          5.82±8.27                                                    17.91±14.68                                                                                              NA
  Middle zone EI, %        3.16±2.52          6.42±6.64                                                    14.72±11.54                                                                                              NA
  Lower zone EI, %         2.77±2.62          6.36±7.36                                                    15.13±13.10                                                                                              NA
  Emphysema distribution                                                                                                                                                                                            
   ULP, n (%)              21 (16.4)          27 (17.9)                                                    61 (48.8)                                                                                                \<0.001[c](#tfn16-copd-11-953){ref-type="table-fn"}
   MHE, n (%)              84 (65.6)          70 (46.4)                                                    37 (39.6)                                                                                                
   LLP, n (%)              23 (18.0)          54 (35.8)                                                    27 (21.6)                                                                                                

**Notes:** Data are presented as mean ± SD or n (%).

*P*\<0.01,

*P*\<0.05 versus controls;

*P*\<0.01 versus asthma patients.

Analysis of Kruskal--Wallis test.

Analysis of Mann--Whitney *U* test.

Analysis of chi-square test.

**Abbreviations:** EI, emphysema index; LAA%-910, percentage of lung voxels with CT attenuation value below −910 HU; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; LLP, lower-lung-zone predominance; LP10A, mean lung attenuation value at the 10th percentile on lung attenuation curve; LP15A, mean lung attenuation value at the 15th percentile on lung attenuation curve; MHE, middle/homogeneous distribution; NA, not available; SD, standard deviation; ULP, upper-lung-zone predominance.

###### 

Characteristics of asthma patients with high and low EI

  Characteristics                    Asthma with high EI (n=32)   Asthma with low EI (n=119)   *P*-value
  ---------------------------------- ---------------------------- ---------------------------- -----------------------------------------------------
  Age, years                         61.3±9.4                     57.4±9.3                     0.046[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Sex, female/male                   6/26                         75/44                        \<0.001[b](#tfn20-copd-11-953){ref-type="table-fn"}
  BMI, kg/m^2^                       22.5±3.2                     26.4±3.7                     \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Smoking, pack-years                29.8±30.0                    7.4±16.1                     \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Current/former/never smoker        11/12/9                      17/11/91                     \<0.001[b](#tfn20-copd-11-953){ref-type="table-fn"}
  Acute exacerbations                1.7±1.1                      0.9±0.7                      \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Postbronchodilator                                                                           
   FEV~1~ % predicted                49.5±16.7                    69.2±22.1                    \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
   FVC% predicted                    84.3±16.4                    89.8±13.4                    0.097[a](#tfn19-copd-11-953){ref-type="table-fn"}
   VC% predicted                     85.9±15.9                    89.8±17.4                    0.133[a](#tfn19-copd-11-953){ref-type="table-fn"}
   FEV~1~/FVC%                       47.9±10.6                    63.9±12.8                    \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Response to β~2~ -agonist                                                                    
   ΔFEV~1~, L                        0.334±0.158                  0.298±0.189                  0.17[a](#tfn19-copd-11-953){ref-type="table-fn"}
   % change in FEV~1~ %              31.2±19.8                    20.1±14.6                    \<0.01[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Percentage of airflow limitation   100%                         60.50%                       \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  %LAA-950, %                        17.1±6.3                     3.3±2.7                      \<0.001[a](#tfn19-copd-11-953){ref-type="table-fn"}
  Per ULP, %                         11 (34.4)                    16 (13.4)                    0.006[b](#tfn20-copd-11-953){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD or n (%).

Analysis of Mann--Whitney *U* test.

Analysis of chi-square test.

**Abbreviations:** BMI, body mass index; EI, emphysema index; ΔFEV~1~, increases in forced expiratory volume in 1 second; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; SD, standard deviation; ULP, upper-lung-zone predominance; VC, vital capacity.

###### 

Characteristics of asthma patients with high EI and COPD patients

  Characteristics               Asthma with high EI (n=32)   COPD (n=125)   *P*-value
  ----------------------------- ---------------------------- -------------- -----------------------------------------------------
  Age, years                    61.2±9.4                     65.8±9.3       0.025[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Sex, female/male              6/26                         32/93          0.494[b](#tfn24-copd-11-953){ref-type="table-fn"}
  BMI, kg/m^2^                  22.5±3.2                     22.6±4.5       0.918[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Smoking, pack-years           29.8±30.0                    34.5±26.6      0.224[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Current/former/never smoker   11/12/9                      57/49/19       0.207[b](#tfn24-copd-11-953){ref-type="table-fn"}
  Acute exacerbations           1.7±1.1                      1.2±0.9        0.012[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Postbronchodilator                                                        
   FEV~1~% predicted            49.5±16.7                    44.3±18.6      0.152[a](#tfn23-copd-11-953){ref-type="table-fn"}
   FVC% predicted               84.3±16.4                    73.6±17.5      0.004[a](#tfn23-copd-11-953){ref-type="table-fn"}
   VC% predicted                85.9±15.9                    76.0±16.2      0.002[a](#tfn23-copd-11-953){ref-type="table-fn"}
   FEV~1~/FVC%                  47.9±10.6                    48.1±12.2      0.862[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Response to β~2~-agonist                                                  
   ΔFEV~1~, L                   0.334±0.158                  0.143±0.009    \<0.001[a](#tfn23-copd-11-953){ref-type="table-fn"}
   % change in FEV~1~%          31.2±19.8                    15.2±12.8      \<0.001[a](#tfn23-copd-11-953){ref-type="table-fn"}
  %LAA-950, %                   17.1±6.3                     15.8±11.9      0.105[a](#tfn23-copd-11-953){ref-type="table-fn"}
  Per ULP, n (%)                11 (34.4)                    61 (48.8)      0.144[b](#tfn24-copd-11-953){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD.

Analysis of Mann--Whitney *U* test.

Analysis of chi-square test.

**Abbreviations:** BMI, body mass index; EI, emphysema index; ΔFEV~1~, increases in forced expiratory volume in 1 second; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; %LAA-950, percentage of lung voxels with CT attenuation value below −950 HU; SD, standard deviation; ULP, upper-lung-zone predominance; VC, vital capacity.

###### 

Multivariate logistic regression for predictors of high EI among asthma patients

  Variable                                    OR      95% CI       *P*-value
  ------------------------------------------- ------- ------------ -----------
  Pack-years of smoking (per 10 pack-years)   1.405   1.13--1.75   0.003
  BMI, kg/m^2^                                0.738   0.63--0.87   \<0.001
  Acute exacerbations                         2.720   1.36--5.4    0.005
  FEV~1~ % predicted (per 10% decrease)       1.428   1.08--1.89   0.013

**Abbreviations:** EI, emphysema index; BMI, body mass index; CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; OR, odds ratio.
